About IgGenix
IgGenix is a company based in San Francisco (United States) founded in 2019 by Stephen Quake and Kari Nadeau.. IgGenix has raised $75 million across 3 funding rounds from investors including Lilly, ARE and Khosla Ventures. IgGenix offers products and services including IGNX001 and SEQ SIFTER. IgGenix operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter San Francisco, United States
- Founders Stephen Quake, Kari Nadeau
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Iggenix, Inc.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$75 M (USD)
in 3 rounds
-
Latest Funding Round
$40 M (USD), Series B
Feb 06, 2023
-
Investors
Lilly
& 6 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of IgGenix
IgGenix offers a comprehensive portfolio of products and services, including IGNX001 and SEQ SIFTER. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Injectable treatment that blocks allergic reactions for peanut allergy
RNA-sequencing tool for identifying rare antibodies in human blood samples
Unlock access to complete
Funding Insights of IgGenix
IgGenix has successfully raised a total of $75M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $40 million completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $40.0M
-
First Round
First Round
(04 Aug 2020)
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2023 | Amount | Series B - IgGenix | Valuation | Alexandria | |
| Jul, 2021 | Amount | Series A - IgGenix | Valuation | Khosla Ventures , Matthias Westman | |
| Aug, 2020 | Amount | Series A - IgGenix | Valuation | Khosla Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in IgGenix
IgGenix has secured backing from 7 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Lilly, ARE and Khosla Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage startups are funded by this venture capital firm.
|
Founded Year | Domain | Location | |
|
Venture capital investments are focused on food allergy solutions.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by IgGenix
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - IgGenix
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Iggenix Comparisons
Competitors of IgGenix
IgGenix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Iggenix
Frequently Asked Questions about IgGenix
When was IgGenix founded?
IgGenix was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is IgGenix located?
IgGenix is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is IgGenix a funded company?
IgGenix is a funded company, having raised a total of $75M across 3 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Aug 04, 2020.
What does IgGenix do?
IgGenix was founded in 2019 and is based in San Francisco, United States. Operations focus on the biotechnology sector, where antibody-based therapeutic platforms are developed to address food allergies. Single-cell genomic technology is utilized to analyze rare human B cells that bind allergens. Immune-modulating activities from the IgG antibody class are incorporated to suppress allergic reactions and monitor conditions.
Who are the top competitors of IgGenix?
IgGenix's top competitors include Spark Therapeutics, BridgeBio and argenx.
What products or services does IgGenix offer?
IgGenix offers IGNX001 and SEQ SIFTER.
Who are IgGenix's investors?
IgGenix has 7 investors. Key investors include Lilly, ARE, Khosla Ventures, AllerFund, and Sean Parker.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.